Detalhe da pesquisa
1.
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes.
Clin Diabetes
; 41(2): 154-162, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37092154
2.
The role of GLP-1 receptor agonists and their fixed combination with insulin in the treatment of type 2 diabetes mellitus.
Vnitr Lek
; 65(4): 284-288, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31091948
3.
[A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)]. / Konsenzuálne terapeutické odporúcanie Slovenskej diabetologickej spolocnosti pre diabetes mellitus 2. typu (2018).
Vnitr Lek
; 64(4): 405-426, 2018.
Artigo
em Tcheco
| MEDLINE | ID: mdl-29791176
4.
A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes.
Eur J Clin Pharmacol
; 71(1): 59-63, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25327507
5.
Variation in KCNQ1 is associated with therapeutic response to sulphonylureas.
Med Sci Monit
; 17(7): CR392-6, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21709633
6.
KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors.
Diabetes Res Clin Pract
; 130: 142-147, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28624668
7.
Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide.
Int J Endocrinol
; 2013: 374858, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23509454
8.
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
Eur J Intern Med
; 23(3): 245-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22385882
9.
Relationship between type 2 diabetes mellitus and hypothalamic-pituitary-adrenal axis.
Wien Klin Wochenschr
; 123(1-2): 28-33, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21165705